5-Day Preoperative Radiotherapy in High-Risk STS Shows Manageable Toxicity

Why It Matters

Condensing pre‑operative RT to five days could streamline sarcoma care and reduce patient burden, yet the high incidence of wound complications, especially with certain reconstruction techniques, may limit its adoption without further evidence.

Key Takeaways

• 110 high‑risk STS patients received 5‑day pre‑op RT.
• Grade ≥2 radiation toxicities occurred in 19% of evaluable patients.
• Major wound complications affected 30% of participants overall.
• Local tissue advancement flaps raised wound risk fourteen‑fold.
• Study limited by single‑center, non‑randomized design.

Pulse Analysis

Pre‑operative radiotherapy has long been a cornerstone of curative intent for high‑grade soft‑tissue sarcoma, typically delivered over five weeks to shrink tumors before resection. A shorter, five‑day regimen promises logistical advantages: reduced treatment time, lower health‑system costs, and less disruption to patients’ daily lives. By delivering a comparable biologic dose in a condensed schedule, clinicians hope to retain the oncologic benefits of pre‑operative RT—smaller target volumes and lower cumulative doses—while improving accessibility for patients who might otherwise face prolonged therapy.

The JAMA Network Open phase‑2 study of 110 patients provides early safety signals for this accelerated approach. Radiation‑related toxicities of grade ≥ 2 were reported in 19% of the 74 evaluable participants, a rate that fell in the later extension cohort, suggesting a learning curve or patient‑selection effect. However, wound morbidity emerged as a more pressing concern: 33 patients experienced major complications, and reconstruction using local tissue advancement flaps amplified the risk fourteen‑fold. These findings underscore that while the condensed radiation schedule appears tolerable, surgical technique and wound‑healing dynamics remain critical determinants of overall outcomes.

For oncologists and surgical teams, the study highlights a trade‑off between treatment convenience and postoperative risk. The authors advocate for randomized trials comparing five‑day hypofractionated regimens with standard or moderately hypofractionated schedules to clarify whether the modest toxicity advantage outweighs the heightened wound‑complication profile. Until such data emerge, careful patient selection—favoring those amenable to primary closure or vascularized grafts—may mitigate adverse events and allow the field to harness the potential efficiencies of ultra‑short pre‑operative radiotherapy.